Search hospitals > Maryland > Bethesda
National Institutes of Health Clinical Center, 9000 Rockville Pike
Claim this profileBethesda, Maryland 20817
Global Leader in Healthy Subjects
Global Leader in Cancer
Conducts research for Tumors
Conducts research for Lymphoma
Conducts research for Syndrome
3382 reported clinical trials
27 medical researchers
Summary
National Institutes of Health Clinical Center, 9000 Rockville Pike is a medical facility located in Bethesda, Maryland. This center is recognized for care of Healthy Subjects, Cancer, Tumors, Lymphoma, Syndrome and other specialties. National Institutes of Health Clinical Center, 9000 Rockville Pike is involved with conducting 3,382 clinical trials across 2,254 conditions. There are 27 research doctors associated with this hospital, such as A P. Chen, John Glod, MD, Nirali N. Shah, and Naoko Takebe.Area of expertise
1Healthy Subjects
Global LeaderStage I
Stage II
TSPO
2Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
A P. ChenNational Institutes of Health Clinical Center2 years of reported clinical research
Expert in Cancer
Expert in Tumors
24 reported clinical trials
67 drugs studied
John Glod, MDNational Cancer Institute Pediatric Oncology Branch8 years of reported clinical research
Studies Brain Tumor
Studies Sarcoma
10 reported clinical trials
13 drugs studied
Nirali N. ShahNational Institutes of Health, Clinical Center7 years of reported clinical research
Studies Leukemia
Studies Acute Myeloid Leukemia
9 reported clinical trials
12 drugs studied
Naoko TakebeNational Institutes of Health Clinical Center7 years of reported clinical research
Studies Cancer
Studies Tumors
7 reported clinical trials
13 drugs studied
Clinical Trials running at National Institutes of Health Clinical Center, 9000 Rockville Pike
Cancer
Tumors
Aplastic Anemia
Breast Cancer
Colorectal Cancer
Lymphoma
Depression
Ovarian Cancer
Endometrial Cancer
Solid Tumors
Enasidenib
for Sinonasal and Skull Base Cancer
Background: Cancers of the nasal cavity or skull base are rare. They often are not diagnosed until they are at an advanced stage, and they often spread to other parts of the body. These cancers may have mutations in a gene called IDH2. Researchers want to find out if a drug (enasidenib) that targets the IDH2 mutation can help people with these cancers. Objective: To test enasidenib in people with cancers of the nasal cavity or skull base. Eligibility: People aged 18 years and older with rare cancers of the nasal cavity or the base of the skull. Their cancer must have an IDH2 gene mutation, and it must have recurred locally or spread to other parts of the body. These cancers can include sinonasal undifferentiated carcinoma; olfactory neuroblastoma; sinonasal large-cell neuroendocrine carcinoma; poorly differentiated sinonasal adenocarcinoma; or chondrosarcoma. Design: Participants will be screened. They will have a physical exam with blood and urine tests and tests of their heart function. They will have imaging scans of their brain, skull base, neck, chest, abdomen, and pelvis. A sample of tumor tissue will be collected. Enasidenib is a tablet taken by mouth with a glass of water. Participants will take the drug once a day, every day, in 28-day cycles. They will not have resting periods between cycles. Participants will visit the clinic on the first day of each cycle to receive the tablets they will need to take at home until the beginning of the next cycle. They will keep a diary to record the time of each dose they take. Participants may remain in the study as long as the drug is helping them....
Recruiting1 award Phase 2
Lurbinectedin + Avelumab
for Bladder Cancer
Background: Small cell carcinoma of the bladder (SCCB) and other high-grade neuroendocrine tumors (HGNET) of the urinary tract are rare but aggressive cancers. Average survival for people diagnosed with SCCB or HGNET is about 1 year. Lurbinectedin and avelumab are drugs that are approved to treat other cancers. Researchers want to see if these drugs can help people with SCCB or HGNET. Objective: To test lurbinectedin with or without avelumab in people with SCCB or HGNET. Eligibility: Adults aged 18 years and older with SCBB or HGNET that returned and spread after treatment. Design: Participants will be screened. They will have a physical exam. They will have blood tests and imaging scans. They may need to have a new biopsy: A small needle will be used to collect a tissue sample from the tumor. Both study drugs are given through a tube attached to a needle inserted into a vein. If participants have already received a drug like avelumab they will receive only lurbinectedin. If patients have not been previously treated with a drug like avelumab they will receive both lurbinectedin and avelumab. All participants will receive their treatment once every 3 weeks for up to 10 years. They will also receive other drugs to relieve adverse effects. Biopsies, blood tests, and imaging scans will be repeated during some study visits. Participants may also have urine tests and tests of their heart function. Participants may remain in the study as long as the treatment is helping them. If they stop treatment, they will have safety visits 14, 30, and 90 days after their last dose. Additional follow-up visits will continue 5 to 10 years.
Recruiting1 award Phase 2
Immunotherapy with TIL
for Cancer
Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient. These cells are called Tumor Infiltrating Lymphocytes, or TIL and we have given this type of treatment to over 200 patients with melanoma. Researchers want to know if TIL shrink s tumors in people with digestive tract, urothelial, breast, or ovarian/endometrial cancers. In this study, we are selecting a specific subset of white blood cells from the tumor that we think are the most effective in fighting tumors and will use only these cells in making the tumor fighting cells. Objective: The purpose of this study is to see if these specifically selected tumor fighting cells can cause digestive tract, urothelial, breast, or ovarian/endometrial tumors to shrink and to see if this treatment is safe. Eligibility: - Adults age 18-72 with upper or lower gastrointestinal, hepatobiliary, genitourinary, breast, ovarian/endometrial cancer, or glioblastoma refractory to standard chemotherapy. Design: Work up stage: Patients will be seen as an outpatient at the NIH clinical Center and undergo a history and physical examination, scans, x-rays, lab tests, and other tests as needed. Surgery: If the patients meet all of the requirements for the study they will undergo surgery to remove a tumor that can be used to grow the TIL product. Leukapheresis: Patients may undergo leukapheresis to obtain additional white blood cells. (Leukapheresis is a common procedure, which removes only the white blood cells from the patient.) Treatment: Once their cells have grown, the patients will be admitted to the hospital for the conditioning chemotherapy, the TIL cells and aldesleukin. They will stay in the hospital for about 4 weeks for the treatment. Follow up: Patients will return to the clinic for a physical exam, review of side effects, lab tests, and scans about every 1-3 months for the first year, and then every 6 months to 1 year as long as their tumors are shrinking. Follow up visits will take up to 2 days.
Recruiting1 award Phase 213 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at National Institutes of Health Clinical Center, 9000 Rockville Pike?
National Institutes of Health Clinical Center, 9000 Rockville Pike is a medical facility located in Bethesda, Maryland. This center is recognized for care of Healthy Subjects, Cancer, Tumors, Lymphoma, Syndrome and other specialties. National Institutes of Health Clinical Center, 9000 Rockville Pike is involved with conducting 3,382 clinical trials across 2,254 conditions. There are 27 research doctors associated with this hospital, such as A P. Chen, John Glod, MD, Nirali N. Shah, and Naoko Takebe.
Where is National Institutes of Health Clinical Center, 9000 Rockville Pike located?
To reach the National Institutes of Health Clinical Center in Bethesda, Maryland:
- From I-495 (Capital Beltway), take Exit 34 and head south on Route 355 (Wisconsin Ave./Rockville Pike).
- Turn right onto West Cedar Lane, then left into the patient entrance on West Drive, open daily from 6 am to 10 pm.
- Outside these hours, use the Commercial Vehicle Inspection Facility on Rockville Pike (Route 355) between North Drive and Wilson Drive, open daily from 10 pm to 6 am. Show a government-issued photo ID and follow signs to the "Clinical Center".
Who should I call to ask about financial aid or insurance network?
**National Institutes of Health (NIH) Clinical Center Contact Information:**
- **General Inquiries:** (301) 496-4000
- **Study Assistance:** 1-800-411-1222 or 1-866-411-1010 (TTY)
- **Cashier's Office:** 301-496-2654
- **Patient Representative:** 301-496-2626
- **Children's School:** 301-496-2077
- **Social Work:** 301-496-2381 (Local), 1-888-676-5668 (Toll-Free)
- **Developmental Therapeutics Clinic:** 1-800-4-Cancer (1-800-422-6237)
- **Patient Recruitment and Liaison Office:** 1-800-411-1222
What insurance does National Institutes of Health Clinical Center, 9000 Rockville Pike accept?
The National Institutes of Health Clinical Center accepts the Federal Employees Health Benefits (FEHB) program. The Foundation for the Advanced Education in the Sciences (FAES) partners with Trustmark and MetLife to provide medical/prescription, dental, and vision insurance plans for NIH Fellows and their families.
What awards or recognition has National Institutes of Health Clinical Center, 9000 Rockville Pike received?
The National Institutes of Health Clinical Center, located in Bethesda, Maryland, is a leading research hospital that has been awarded the 2011 Lasker~Bloomberg Public Service Award for its innovative therapy and transformation of scientific advances into practical applications. It receives significant funding for research and care, primarily through annual discretionary appropriations. Over 84% of the NIH budget supports extramural research, funding grants, contracts, and awards to universities and other research institutions.